Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1993-10-18
1995-12-19
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
560121, A61K 31557, C07C40500
Patent
active
054768721
ABSTRACT:
Compounds of the formula ##STR1## where the hatched lines indicate alpha (.alpha.) configuration, a solid triangle is used to indicate beta (.beta.) configuration, lines on both sides of a double bond indicate cis (Z) configuration, and lines on opposite sides of the double bond indicate trans (E) configuration; R.sub.1 is alkyl of 1-10 carbons, C.sub.1 -C.sub.10 alkylphenyl, phenyl-C.sub.1 -C.sub.10 alkyl, or alkenyl of 2 to 10 carbons and having 1 to 3 double bonds; R.sub.2 is Z--OR.sub.3, Z--OCOR.sub.3, Z--OCONHR.sub.3, Z--OCOOR.sub.3, Z--NR.sub.4 R.sub.5, Z--NR.sub.4 COR.sub.3, Z--NR.sub.4 SO.sub.2 R.sub.3, Z--COOR.sub.3, Z--CONR.sub.4 R.sub.5, Z--CHO; Z is (CH.sub.2).sub.n where n is 1-6, or Z is an alkenyl group having 2 to 6 carbons and 1 or 2 double bonds, R.sub.3 is H, alkyl of 1-6 carbons, alkenyl of 2 to 6 carbons or phenyl, R.sub.4 and R.sub.5 independently are H or alkyl of 1 to 6 carbons, have ocular hypotensive activity.
REFERENCES:
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5139491 (1992-08-01), Chan et al.
patent: 5238961 (1993-08-01), Woodward et al.
patent: 5288754 (1994-02-01), Woodward
Bito, L. Z., Arch. Ophthalmol, 105, 1036 (1987).
Bito, L. Z. Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S. M. and Neufeld, A. H. eds., New York, Grune & Stratton, 1984 pp. 477-505).
Bito, L. Z., Biological Protection with Prostaglandins, Cohen, M. M., ed., Boca Raton Fla. CRC Press Inc., 1985, pp. 231-252.
M. S. Starr, Exp. Eye Res. 11, 170-177 (1971).
Nilsson et al., Invest, Ophthalmol. Vis. Sci. 28 (suppl), 284 (1987).
Siebold et al., Prodrug 5, 3 (1989).
Woodward, et al., Prostaglandin F.sub.2a Effects on Intraocular Pressure Negatively Correlate with FP-Receptor Stimulation, Investigative Ophthalmology & Visual Science, vol. 30, No. 8, Aug. 1989.
Zajacz, et al., Effect on Human Eye of Prostaglandin and a Prostaglandin Analogue Used to Induce Abortion, The Eye: Reproduction, Obstetrics and Gynecology, 4, 316 (1976).
Chan Ming Fai
Garst Michael E.
Roof Michael B.
Syage Elizabeth T.
Woodward David F.
Allergan Inc.
Baran Robert J.
Gerstl Robert
Szekeres Gabor L.
Voet Martin A.
LandOfFree
1,11-diesters of prostaglandin-F.sub.2.alpha. having a polar es does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,11-diesters of prostaglandin-F.sub.2.alpha. having a polar es, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,11-diesters of prostaglandin-F.sub.2.alpha. having a polar es will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-992334